Abstract
This cross-sectional study examines how use of glucagon-like peptide-1 (GLP-1) receptor agonists varies among US adults with diabetes with or without a history of cancer.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureOlinto Linares-Perdomo, Damon Klebe, Fumiko Chino, Bismarck C. Odei
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
10.1016/s2213-8587(21)00203-5 · 2021
Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2024.
10.2337/dc24-s009 · 2024
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes.
10.1016/j.jacc.2020.05.037 · 2020
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
10.1200/jco.2016.70.5400 · 2017
A population-based study of cardiovascular disease mortality risk in US cancer patients.
10.1093/eurheartj/ehz766 · 2019
GLP-1 RA use and survival among older adults with cancer and type 2 diabetes.
10.1001/jamanetworkopen.2025.21887 · 2025
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.
10.1016/s0140-6736(07)61602-x · 2007
Unresolved referenced work
Kept as external metadata until matched
10.15620/cdc/174616
10.15620/cdc/174616
No additional external references are available.